1-8 of 8
Oliver Giles Best, PhDBSc
Close
Sort by
Journal Articles

Venetoclax Is Synergistic with Idelalisib or MK2206 Against Primary CLL Cells in an in Vitro Model of the Microenvironment

Yandong Shen, BMedSc (Hon) PhD, Kyle R Crassini, MBBS,BSc, Narjis Fatima, BSMedTech,MPhil, Richard Christopherson, PhDEmeritus Professor, Stephen P. Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 5443.
https://doi.org/10.1182/blood-2019-130082
Published: 2019
Journal Articles

DNA Damage in Haemopoeitic Stem Cells Impacts on Neutrophil and Platelet Engraftment Following Autologous Transplantation

Lijun Bai, PhD MBBS, Oliver Giles Best, PhDBSc, Wei Xia, PhD MBBS, Lyndsay Peters, Kelly Wong, Christopher Ward, PhD MBBChir, Matthew Greenwood, FRACP, FRCPA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4622.
https://doi.org/10.1182/blood-2018-99-115530
Published: 2018
Journal Articles

Inhibition of AKT By MK2206 but Not PI3-Kinase δ By Idelalisib Is Effective Against CLL Cells in an In Vitro Model of the Hypoxic Microenvironment

Yandong Shen, BMedSc (Hon), Kyle R Crassini, MBBS,BE,BSc, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Richard Christopherson, PhDEmeritus Professor, Oliver Giles Best, PhDBSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 5340.
https://doi.org/10.1182/blood.V130.Suppl_1.5340.5340
Published: 2017
Journal Articles

Deficiencies in Immunoglobulin Classes and Immunoglobulin G Subclasses Are Associated with Shorter Treatment Free Survival and Overall Survival in CLL

Kyle R Crassini, MBBS,BE,BSc, Eva Zhang, MBBS, Shalini Balendran, MBBS, Jane Freeman, BA,FRACP,FRCPA,MBBS,MPhil,MSc, Oliver Giles Best, PhDBSc, Cecily Forsyth, FRACP, FRCPA, MBBS, Naomi Mackinlay, Ping Han, MDPhD, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS
Journal: Blood
Blood (2017) 130 (Supplement 1): 5321.
https://doi.org/10.1182/blood.V130.Suppl_1.5321.5321
Published: 2017
Journal Articles

Analysis of mRNA Expression in Peripheral, Bone Marrow and Lymph Node Dervied CLL Cells Using the Nanosting Ncounter Platform

Kyle R Crassini, MBBS,BE,BSc, Yandong Shen, BMedSc (Hon), Richard Christopherson, PhDEmeritus Professor, William S. Stevenson, MBBS,PhD, Stephen Mulligan, PhDFRACP,FRCPA,MBBS, Oliver Giles Best, PhDBSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 4279.
https://doi.org/10.1182/blood.V130.Suppl_1.4279.4279
Published: 2017
Journal Articles

Dual Inhibition of PIM and PI3-Kinase By Ibl-202 Is Highly Synergistic Compared to Mono-Molecular Inhibition and Represents a Novel Treatment Strategy for Chronic Lymphocytic Leukemia

Oliver Giles Best, PhDBSc, Kyle Crassini, MBBS BSc, Michael O'Neill, PhD, Michael E O'Dwyer, MD FRCPI, FRCPath, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA
Journal: Blood
Blood (2014) 124 (21): 4693.
https://doi.org/10.1182/blood.V124.21.4693.4693
Published: 2014
Journal Articles

The Oxazolidinone Derivative Locostatin Induces Apoptosis in CLL Cells through Inhibition of AKT and MAPK-ERK1/2 Signaling Under Conditions That Mimic the Tumor Microenvironment

Oliver Giles Best, PhDBSc, Tahni Pyke, BSc (Hons), Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA
Journal: Blood
Blood (2014) 124 (21): 3326.
https://doi.org/10.1182/blood.V124.21.3326.3326
Published: 2014
Journal Articles

MEK1/2 Inhibition By MEK162 Is Effective Against Chronic Lymphocytic Leukaemia Cells Under Conditions That Mimic Stimulation of B-Cell Receptor-Mediated Signaling

Kyle Crassini, MBBS,BSc, William S Stevenson, MBBS, PhD, Stephen P. Mulligan, MBBS (Hons), PhD, FRACP, FRCPA, Oliver Giles Best, PhDBSc
Journal: Blood
Blood (2014) 124 (21): 3330.
https://doi.org/10.1182/blood.V124.21.3330.3330
Published: 2014